JP2020521774A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521774A5 JP2020521774A5 JP2019565504A JP2019565504A JP2020521774A5 JP 2020521774 A5 JP2020521774 A5 JP 2020521774A5 JP 2019565504 A JP2019565504 A JP 2019565504A JP 2019565504 A JP2019565504 A JP 2019565504A JP 2020521774 A5 JP2020521774 A5 JP 2020521774A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- combination
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017086624 | 2017-05-31 | ||
| CNPCT/CN2017/086624 | 2017-05-31 | ||
| PCT/IB2018/053839 WO2018220546A1 (en) | 2017-05-31 | 2018-05-30 | Crystalline forms of 5-bromo-2,6-di(1 h-pyrazol-1-yl)pyrimidin-4-amine and new salts |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521774A JP2020521774A (ja) | 2020-07-27 |
| JP2020521774A5 true JP2020521774A5 (enExample) | 2021-07-26 |
| JP7273732B2 JP7273732B2 (ja) | 2023-05-15 |
Family
ID=62778954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565504A Active JP7273732B2 (ja) | 2017-05-31 | 2018-05-30 | ５－ブロモ－２，６－ジ（１ｈ－ピラゾール－１－イル）ピリミジン－４－アミン及び新たな塩の結晶形 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10933064B2 (enExample) |
| EP (1) | EP3630751B1 (enExample) |
| JP (1) | JP7273732B2 (enExample) |
| KR (1) | KR20200018503A (enExample) |
| CN (1) | CN110944995B (enExample) |
| AR (1) | AR111906A1 (enExample) |
| AU (1) | AU2018277241B2 (enExample) |
| BR (1) | BR112019025149A2 (enExample) |
| CA (1) | CA3065475A1 (enExample) |
| CL (2) | CL2019003468A1 (enExample) |
| IL (2) | IL270795B2 (enExample) |
| JO (1) | JOP20190279A1 (enExample) |
| MX (1) | MX2021014104A (enExample) |
| PH (1) | PH12019502703A1 (enExample) |
| RU (2) | RU2022102355A (enExample) |
| TW (1) | TWI814725B (enExample) |
| WO (1) | WO2018220546A1 (enExample) |
| ZA (1) | ZA201907610B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019503349A (ja) * | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Ｐｄ−１に対する抗体分子およびその使用 |
| JOP20190279A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| CA2398274C (en) * | 2000-02-25 | 2009-09-22 | F. Hoffmann-La Roche Ag | Adenosine receptor modulators |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| EP1537878B1 (en) | 2002-07-03 | 2010-09-22 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2005058883A1 (en) | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101607288B1 (ko) | 2005-07-01 | 2016-04-05 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US20070208040A1 (en) * | 2006-03-02 | 2007-09-06 | Elfatih Elzein | A2a adenosine receptor antagonists |
| WO2008110891A2 (en) | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
| US8153064B2 (en) | 2007-03-22 | 2012-04-10 | Doebler Ii Robert W | Systems and devices for isothermal biochemical reactions and/or analysis |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| WO2010029435A1 (en) | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| TWI729512B (zh) | 2008-12-09 | 2021-06-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| AU2012288413B2 (en) | 2011-07-24 | 2016-10-13 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| PT2992017T (pt) | 2013-05-02 | 2021-01-29 | Anaptysbio Inc | Anticorpos dirigidos contra a morte programada 1 (pd-1) |
| HK1221964A1 (zh) | 2013-05-31 | 2017-06-16 | Sorrento Therapeutics, Inc. | 与pd-1结合的抗原结合蛋白 |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| RS63571B9 (sr) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva |
| PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| SI3334431T1 (sl) * | 2015-08-11 | 2020-01-31 | Novartis Ag | 5-bromo-2,6-di-(1h-pirazol-l-il)pyrimidin-4-amin za uporabo v zdravljenju raka |
| WO2018146612A1 (en) * | 2017-02-10 | 2018-08-16 | Novartis Ag | 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer |
| JOP20190279A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
-
2017
- 2017-06-16 JO JOP/2019/0279A patent/JOP20190279A1/ar unknown
-
2018
- 2018-05-30 RU RU2022102355A patent/RU2022102355A/ru unknown
- 2018-05-30 WO PCT/IB2018/053839 patent/WO2018220546A1/en not_active Ceased
- 2018-05-30 CA CA3065475A patent/CA3065475A1/en active Pending
- 2018-05-30 US US16/616,844 patent/US10933064B2/en not_active Expired - Fee Related
- 2018-05-30 IL IL270795A patent/IL270795B2/en unknown
- 2018-05-30 BR BR112019025149-9A patent/BR112019025149A2/pt not_active IP Right Cessation
- 2018-05-30 EP EP18734945.1A patent/EP3630751B1/en active Active
- 2018-05-30 RU RU2019138329A patent/RU2019138329A/ru unknown
- 2018-05-30 IL IL291721A patent/IL291721B2/en unknown
- 2018-05-30 AU AU2018277241A patent/AU2018277241B2/en not_active Ceased
- 2018-05-30 JP JP2019565504A patent/JP7273732B2/ja active Active
- 2018-05-30 PH PH1/2019/502703A patent/PH12019502703A1/en unknown
- 2018-05-30 CN CN201880035190.7A patent/CN110944995B/zh active Active
- 2018-05-30 KR KR1020197038580A patent/KR20200018503A/ko not_active Ceased
- 2018-05-31 AR ARP180101452A patent/AR111906A1/es unknown
- 2018-05-31 TW TW107118638A patent/TWI814725B/zh not_active IP Right Cessation
-
2019
- 2019-11-18 ZA ZA2019/07610A patent/ZA201907610B/en unknown
- 2019-11-27 CL CL2019003468A patent/CL2019003468A1/es unknown
- 2019-11-27 MX MX2021014104A patent/MX2021014104A/es unknown
-
2021
- 2021-01-25 US US17/156,785 patent/US11654144B2/en active Active
- 2021-10-12 CL CL2021002667A patent/CL2021002667A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7250724B2 (ja) | 抗ｈｅｒ２抗体及び免疫複合体 | |
| CN111801334B (zh) | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 | |
| TWI826828B (zh) | 抗her3抗體-藥物結合物及含有其之醫藥及醫藥組成物 | |
| AU2016306090B2 (en) | 5-bromo-2,6-di-(1H-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| US20200179511A1 (en) | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor | |
| JP2017186337A5 (enExample) | ||
| CN112566661B (zh) | 喹啉衍生物与抗体的药物组合 | |
| TW202122115A (zh) | 包含抗人類ｒｏｒ１抗體之抗體—藥物結合物及其用途 | |
| JP2018503365A5 (enExample) | ||
| CN110087730A (zh) | 使用包含parp抑制剂的组合产品治疗癌症 | |
| IL263466B2 (en) | Anti-CD3 antibodies and methods of using them | |
| JP2022116269A5 (enExample) | ||
| CN107148285A (zh) | 吡咯并苯并二氮杂*‑抗体缀合物 | |
| JP2014533279A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| WO2024051796A1 (en) | Albumin binding proteins, fusion proteins and uses thereof | |
| JP2020521774A5 (enExample) | ||
| JP2019524714A5 (enExample) | ||
| RU2019138329A (ru) | Кристаллические формы 5-бром-2,6-ди(1н-пиразол-1-ил)пиримидин-4-амина и новых солей | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| CN120000805A (zh) | 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途 | |
| TW202509062A (zh) | 抗b7-h3抗體及其用途 | |
| JP2020507569A5 (enExample) | ||
| JPWO2019143607A5 (enExample) | ||
| JPWO2020076799A5 (enExample) |